HIV and Heart Disease: A Growing Concern

For years, HIV infection was considered primarily an immunological threat. Though, with advancements in antiretroviral therapy (ART) extending the lifespan of individuals living with HIV, a new challenge has emerged: an increased risk of cardiovascular disease (CVD). This article explores the complex relationship between HIV and heart health, examining the underlying causes, manifestations, and future directions for research.

The Evolving Landscape of HIV and CVD

Historically, before the widespread use of ART, HIV-associated CVD primarily manifested as HIV-associated cardiomyopathy, often linked to severe immune deficiency. As ART has grow more effective in suppressing viral load and restoring immune function, the nature of cardiac complications in people living with HIV has become more subtle, yet the overall incidence of CVD remains elevated. 1

Prevalence of Cardiac Involvement in HIV

Studies indicate a significant prevalence of cardiac involvement among individuals with HIV, ranging from 28% to 73%. 1 This highlights the importance of cardiac monitoring and preventative strategies in HIV care.

Understanding the Pathogenesis of HIV-Associated CVD

The exact mechanisms driving HIV-associated CVD are multifaceted and continue to be investigated. Advances in cardiac imaging and immunology are deepening our understanding of this complex interplay. Key areas of research include:

• Direct Viral Effects: While less common with effective ART, HIV can directly infect cardiac cells, contributing to inflammation and dysfunction.
• Inflammation: Chronic immune activation, even with viral suppression, can lead to systemic inflammation, damaging blood vessels and the heart.
• Traditional Risk Factors: People living with HIV often have a higher prevalence of traditional CVD risk factors like hypertension, hyperlipidemia, and diabetes.
• ART-Related Effects: Some ART regimens have been associated with metabolic abnormalities that can increase CVD risk.

The pathogenesis of CVD linked to HIV infection continues to be a focus of intense speculation. 2

Common Cardiac Manifestations

HIV-associated CVD can manifest in various forms, including:

• Cardiomyopathy: Weakening of the heart muscle, leading to heart failure.
• Coronary Artery Disease: Narrowing of the arteries supplying blood to the heart.
• Heart Failure: The heart’s inability to pump enough blood to meet the body’s needs.
• Ventricular Dysfunction: Impaired ability of the heart’s ventricles to contract and relax properly.

Diagnosis and Monitoring

Early detection and diagnosis are crucial for managing HIV-associated CVD. Diagnostic tools include:

• Electrocardiogram (ECG): To assess heart rhythm.
• Echocardiogram: To visualize heart structure and function.
• Cardiac Magnetic Resonance Imaging (MRI): Provides detailed images of the heart.
• Biomarkers: Blood tests to detect markers of cardiac damage or inflammation.

Future Research Directions

Further research is needed to address key evidence gaps in the field and improve our understanding of HIV-CVD interactions, particularly within populations originating from high-endemic regions like sub-Saharan Africa. 2 Areas of focus include:

• Investigating the long-term effects of ART on cardiac health.
• Identifying novel biomarkers for early detection of CVD.
• Developing targeted interventions to reduce inflammation and improve cardiovascular outcomes.

A recent review significantly enhances the understanding of HIV-associated cardiomyopathy, providing valuable insights for clinicians and researchers. 3

Key Takeaways

• Individuals living with HIV have an increased risk of cardiovascular disease.
• The nature of HIV-associated CVD has evolved with the advent of ART.
• Early detection, diagnosis, and management of CVD are crucial in HIV care.
• Ongoing research is essential to improve our understanding and treatment of this complex condition.